Optogenetics provides an array of elements for specifi c biophysical control, while designer chemogenetic receptors provide a minimally invasive method to control circuits in vivo by peripheral injection. We developed a strategy for selective regulation of activity in specifi c cells that integrates opto-and chemogenetic approaches, and thus allows manipulation of neuronal activity over a range of spatial and temporal scales in the same experimental animal. Light-sensing molecules (opsins) are activated by biologically produced light through luciferases upon peripheral injection of a small molecule substrate. Such luminescent opsins, luminopsins, allow conventional fi ber optic use of optogenetic sensors, while at the same time providing chemogenetic access to the same sensors. We describe applications of this approach in cultured neurons in vitro, in brain slices ex vivo, and in awake and anesthetized animals in vivo.
Introduction
Currently, there are two major approaches to control activity o f genetically defi ned neurons in the brain of freely behaving animals: chemogenetic approaches that utilize diffusible small molecules [ 1 ] and optogenetic approaches that utilize externally delivered light [ 2 ] . The two methods have their own distinct merits; optogenetics offers the advantage of temporal precision while chemogenetic approaches offer scalability and ease of application. Combining these two approaches within single molecules complements each other and allows the use of either mode of interrogation in the same brain circuit. Such molecular actuators would allow acute activation with precise time resolution in defi ned spaces, as well as chronic and noninvasive control of entire populations throughout the brain through the same molecules.
Luminopsins (luminescent opsins or LMOs) were developed to achieve combined chemo-and optogenetic manipulation [ 3 ] . They are fusion proteins of a light-emitting luciferase and a lightsensing opsin ( see Fig. 1 ). Application of the luciferase substrate, coelenterazine (CTZ) , leads to emission of photons that is sufficient to activate the coupled opsin. We established proof of concept of this technology by using fusion proteins that directly link Gaussia luciferase (GLuc; [ 4 , 5 ] ) to Chlamydomonas channelrhodopsin 2 (ChR2; [ 6 ] ) or Volvox channelrhodopsin 1 (VChR1; [ 7 ] ). As for inhibition, we were able to harness bioluminescence from engineered Renilla luciferase (Nano-lantern; [ 8 ] ) for activation of Natronomonas halorhodopsin [ 9 ] (inhibitory luminopsin or iLMO) . When these fusion proteins are expressed in neurons, bright bioluminescence from GLuc and Nano-lantern was able to excite or silence a neuronal population, respectively, in cultured neurons in vitro, in brai n slices ex vivo, and in awake and anesthetized animals upon application of CTZ. Moreover LMO and iLMO were able to elicit specifi c motor behavior in awake animals in vivo [ The same optogenetic element, when fused to a luciferase (here: Gaussia luciferase, Gluc) by a 15-amino acid linker, can also be activated by "biological" light, which is produced when the attached luciferase catalyzes oxidation of the supplied substrate coelenterazine (CTZ). Fused to the C-terminus of the optogenetic element is the fl uorescent reporter YFP, allowing identifi cation of cells expressing the element. The optogenetic element can be a channel or a pump, and depending on its biophysical properties can activate (LMO) or inhibit (iLMO) a neuron LMOs retain the capability for conventional optogenetic control of neuronal activity. Light from a physical source (e.g. arc lamp, laser, LED) through optical fi bers can activate the opsin moiety similar to when they are expressed by themselves without luciferase . As chemogenetic probes, however, LMOs have characteristics distinct from conventional chemogenetic probes such as DREADDs [ 10 ] . First, chemogenetic access is mediated by opsins instead of G-protein coupled receptors. Thus, there are no requirements for additional signaling pathways for LMOs to function. Second, while there is commonly one designer receptor each for activation and silencing, for example Gq and Gi DREADDs, respectively, LMOs can capitalize on the entire molecular palette of optogenetic actuators, which have a wide range of kinetics and sensitivity, and which can be matched with luciferases with a wide variety of emission spectra. Third, while there is a single designer drug (CNO) for activating both Gq and Gi DREADDs, different luciferases utilize different substrates, making multiplexing feasible. For example, hCTZ, a 2-deoxy derivative of native coelenterazine, which we use as a substrate for our RLuc-based inhibitory LMO (iLMO), cannot be used by Gaussia luciferase, which only emits light with native CTZ . Lastly, the approach is unique in that LMOs integrate opto-and chemogenetic approaches, and thus allow manipulation of neuronal activity over a range of spatial and temporal scales in the same experimental animal.
In this chapter, we will detail critical aspects of working with LMOs for combined opto-and chemogenetic manipulation of neuronal activity. We will address handling and application of the luciferase substrate, simultaneous bioluminescence imaging and electrophysiological and behavioral readouts in vitro and in vivo using LMOs.
Materials
Standard equipment and materials used for the applicat ion of interest will suffi ce (tissue culture, single-cell patch clamp recording, multielectrode array recording, brain slice recording, in vivo electrophysiology , behavioral testing). Detailed below are materials we routinely use for tissue culture experiments, and supplies and procedures for preparing the luciferase substrate.
1. Tissue culture plasticware (4-well plates, 24-well plates, 12-well plates).
2. 12 or 18 mm poly-D -lysine-coated glass coverslips.
3. 293T human embryonic kidney fi broblasts.
4. Rat embryonic cortical tissue for preparing primary neurons .
Cell Culture
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. suppDMEM: Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10 % fetal bovine serum, 1× Nonessential Amino Acids, 2 mM GlutaMax, 100 U penicillin and 0.1 mg streptomycin per milliliter. Store at 4 °C. Warm to at least room temperature before use.
6. Serum-NB: Neurobasal Medium (NB) containing 1× B27, 2 mM Glutamax, and 5 % FBS (medium for neuron plating) or 2 % FBS (medium for MEA cultures).
7. Plain-NB: Neurobasal Medium (NB) containing 1× B27, 2 mM Glutamax without any serum.
8. All-trans retinal : Prepare, in a dark environment, a 10 mM stock by dissolving 25 mg in 8.8 ml ETOH, aliquot, and store at −80 °C. As needed, prepare a 1:10 dilution in PBS to obtain a working stock of 1 mM, which can be kept at 4 °C and protected from light for a few days. Add to the culture medium directly or after further dilution for a fi nal concentration of 1 μM.
Coelenterazine (CTZ), native as well as analogs (hCTZ, eCTZ, etc.), can be commercially obtained from several sources (Note: they differ in purity).
! CTZ should always be protected from light ! 1. Acidifi ed alcohol (ethanol or methanol): 0.06 N HCl in alcohol; add 0.2 ml 3 N HCl to 10 ml alcohol.
2. Cyclodextrin: CTZ can be solubilized in (2-Hydroxypropyl) β-cyclodextrin, as originally described by Teranishi and Shimomura [ 11 ] , and used by Naumann et al. in live zebrafi sh [ 12 ] . The amount of cyclodextrin used depends on the amount of CTZ being complexed and can be determined from ref. 11 , Fig. 3 . After dissolving cyclodextrin in PBS, fi lter-sterilize and add to CTZ dissolved in a small volume of ethanol. We typically dissolve 250 μg CTZ in 10 μl of ethanol and dilute it with 500 μl of 20 mM β-cyclodextrin to reach a stock concentration of 600 μM CTZ. Stocks are then kept frozen and protected from light until they are ready for use. On the day of the experiment, a stock aliquot is thawed and diluted with aqueous solvent (PBS, saline) to the desired concentration.
3. NanoFuel Solvent (NanoLight Technology): a proprietary solvent for coelenterazine. Native coelenterazine can be dissolved in a ten times higher concentration compared to 100 % ethanol or methanol. In our experience, NanoFuel-dissolved CTZ emits more bioluminescence than ethanol-dissolved CTZ when applied at the same fi nal concentration. We dissolve CTZ at 50 mM, a concentration higher than the company's recommendation, to minimize the amount of solvent used and avoid 5. Water-soluble coelenterazine (NanoLight Technology): CTZ (native or h) has nontoxic additives for water-solubility and is formulated to be isosmotic and easily secreted by the kidneys. It is safe for repeated intravenous injections and at high concentrations (up to 500 μg/100 μl) achieving very high coelenterazine levels within the body and leading to high bioluminescence signals [ 13 ] .
Methods
While the goal is to use tools for targeted modifi cation of neuronal activity in the intact living brain of a behaving animal, there are several applications in vitro, specifi cally in cultured cells. These applications range from simply testing constructs or validating viral vector preparations for expression of bioluminescence to studying neuronal networks in long-term cultures to investigating network connections in brain slices. HEK cells provide a convenient heterologous expression system to test and verify new luminopsin constructs, while primary neurons are usually needed to test viral preparations with neuron-specifi c promoters.
1. Grow HEK cells in medium of choice such as suppDMEM at 37 °C and 5 % CO 2 in a humidifi ed atmosphere. 5. At the day of electrophysiology experiments (2-3 days after transfection of DNA) transfer coverslips from tissue culture wells to a recording chamber.
Isolate primary cortical or hippocampal neurons ( see Note 4 )
and determine cell number. Adjust cells to 1-2.5 × 10 5 per 0.5 ml in Serum-NB. Using sterile forceps, place poly-D -lysine-coated glass coverslips ( see Note 5 ) into as many wells as needed (24-well for 12-mm coverslips; 12-well for 18-mm coverslips). Seed 0.5 ml per well cells onto coverslips. Together with the dishes of seeded neurons place a culture tube in the incubator with its lid slightly loosened, containing Plain-NB medium suffi cient to add 1 ml per seeded well (pre-equilibrated Plain-NB).
2. Neurons can be transfected with LMOs using one of the following methods: Lipofection: low effi ciency; highest toxicity; ideal when testing constructs in single cells by patch-clamp recording.
Electroporation : moderate effi ciency; moderate toxicity; requires special equipment (e.g. Lonza Nucleofector) and a higher number of cells. Typically done before seeding.
Viral transduction: highest effi ciency; least toxic; ideal when examining activity of many neurons at a time using a multielectrode array (MEA).
For lipofection, collect 0.5 ml of conditioned culture medium from each well 1 or 2 days after medium change-out in step 3 below (DIV2 or DIV3) and save in a culture tube (we usually collect 2 ml per 4-well dish and save in a separate 15 ml tube for each 4-well dish). Keep tubes in incubator with lid slightly loosened to allow air exchange. Transfect cells in the remaining 0.5 ml medium per well with a luminopsin construct. For transfection of neurons to be used for patch clamping, we use Lipofectamine 2000 according to the manufacturer's recommendations, except
Primary Neurons
that less of the recommended amount of Lipofectamine and DNA per well is used (per well of a 4-well or 24-well dish: 0.2 μl Lipofectamine, a tenth of the recommended amount; 200 ng plasmid DNA, a quarter of the recommended amount). Again, it is convenient to set up transfections for 5 wells per construct (1 μg DNA/250 μl OptiMEM; 1 μl Lipofectamine/250 μl OptiMEM), and transfect 4 wells per 4-well dish. Change out medium 4 h after transfection with the prewarmed and pre-equilibrated saved medium from above ( see Note 6 ).
For electroporation , we follow the manufacturer's recommendations with slight modifi cations. In brief, spin down up to six million cells per reaction in a 1.5 ml tube. Resuspend the cells in 100 μl of the proprietary solution provided or in DPBS with calcium, magnesium, glucose, and pyruvate. Add and mix with 2 μg of LMO DNA. Transfer the cell suspension into a cuvette. After electroporation, using the recommended parameters for primary neurons , add 500 μl prewarmed, CO 2 -equilibrated low-calcium recovery medium (i.e. RPMI) and transfer the cell suspension into the original tube. Incubate the tube in a CO 2 tissue-culture incubator for 5 min before seeding onto coverslips in a well fi lled with prewarmed, CO 2 -equilibrated Serum-NB at a density higher than that used for lipofection.
For viral transduction, add high titer virus (>10 8 infectious units/ml lentivirus , >10
11 vg/ ml AAV) to the Plain-NB medium used in step 1 . Use viral preparations with a multiplicity of infection (MOI) > 10 to ensure near 100 % transduction effi ciency (Fig. 2 ) . Depending on the promoter, expression can typically be visualized by fl uorescence microscopy 3-4 days after infection with lentivirus , and 7-10 days after infection with AAV.
3. Regardless of the method of transfection , the next day after plating (day in vitro 1, DIV1), remove Serum-NB medium completely from neurons and replace with 1 ml per well prewarmed and pre-equilibrated Plain-NB medium. Carry out the medium exchange well by well, so as to not leave neurons without medium for more than a few seconds. 6. On the day of electrophysiological experiments transfer coverslips from tissue culture wells to the recording chamber. Coverslips should be immediately perfused with recording buffer to minimize amount of time coverslips are exposed to air.
For a simple bioluminescence assessment (i.e. bioluminescence intensity and emission spectrum), luminometers provide the most sensitive and quantitative measurements. They are specifi cally designed to measure photon emission upon time-controlled substrate injection, usually in a plate format (96-well plate in the basic models, various plate formats in the higher end models). Alternatively, we have utilized bioluminescence imagers designed for in vivo imaging (see below) and obtained satisfactory results.
If none of the above is available, a good option is imaging systems designed for chemiluminescence, such as image documenting systems for Western blots equipped with a cooled CCD camera (e.g. Fuji Film LAS-3000, Li-Cor Odyssey Fc). For high-emission luciferases, even common gel documentation systems can be used ( see Fig. 3 ).
Simultaneous imaging with electrophysiologic al recordings is addressed in each individual section below. The effects of LMOs on neuronal fi ring can be assessed in primary neurons in culture. Concurrent imaging of bioluminescence helps to establish a causal relationship between biological light and activation of LMOs.
Bioluminescence Imaging In Vitro
1. Cells are imaged and recorded using an upright or inverted epifl uorescence microscope equipped with a 40× 0.8 NA water immersion objective or a 60× 1.35 NA oil immersion objective, respectively, an arc lamp, an electronic shutter, a GFP fi lter cube, and a cooled CCD camera or sCMOS camera with acquisition software. The recording chamber is constantly superfused with the extracellular solution at ~500 μl/min. Experiments are carried out at room temperature.
2. Locate an LMO-positive cell by its fl uorescent-tag expression.
3. Obtain whole-cell recording under voltage or current clamp mode.
4. We routinely measure photocurrent to conventional wide-fi eld photostimulation using the lamp and an appropriate fi lter cube (e.g. a GFP fi lter cube for ChR2). The measured photocurrents refl ect the total functional surface expression level of LMO of the cell.
5. CTZ-induced photocurrents can be measured under voltage clamp. Effects of CTZ on spiking can be recorded under current clamp. The effect of inhibitory LMOs should be assessed under constant action potential fi ring, which can be evoked by a train of brief peri-threshold current injection (note: large current injection can mask subtle effects of CTZ). Immediately before application, reconstitute CTZ in the extracellular solution at 100 μM and bath-apply CTZ solution (~0.5 ml) to Fig. 3 Bioluminescense imaging in 96-well plate format. HEK cells (50,000 per well) transfected with LMOs were plated. Forty-eight hours later bioluminescence intensities were measured after adding different concentrations of CTZ (1-100 μM fi nal concentrations). Images were taken with a LiCor Odyssee Fc using the chemiluminescence channel ( a ) and with a Caliper IVIS Kinetic system for in vivo imaging ( b ). Region of Interest (ROI) can be selected and bioluminescence intensity can be quantifi ed a recording chamber ( see Note 8 for different options) (Fig. 4 ) . Bioluminescence is imaged concurrently throughout the recording through the camera ( see Note 9 for specifi c settings).
Intracellular Recording In Vitro
To synchronize the two recordings, an exposure signal from the camera can be used to trigger electrophysiological recording. To maximize bioluminescence collection, move the fi lter turret to an open position before CTZ application. For bioluminescence imaging the microscope needs to be in complete darkness ( see Note 10 ).
6. Measure photocurrent in response to direct photostim ulation by lamp after CTZ application to confi rm recording conditions have not changed.
Recordings from multiple neurons at a time using a multielectrode array (MEA) provides not only a convenient and high-throughput method [ 14 ] , but also enables analysis on change in network dynamics after activation of LMOs. 3. The next day (DIV1) transduce cultures with AAV or lentivirus with an MOI >10 to achieve close to 100 % transduction (Fig. 5 ).
Extracellular Recording In Vitro
4. Change half-volume of media every 3-4 days.
5. Spontaneous synchronous bursting activity can be recorded around DIV 14. Insert an MEA into the appropriate headstage and connect to an amplifi er. Allow the MEA to equilibrate to achieve a stable baseline of activity.
6. Optical stimulation can be conducted with an external LED or lamp since the MEAs are optically clear. Brain slice preparations retain innate synaptic connection to some degree. Recordings from LMO-expressing brain slices enable precise control of a given network using conventional optogenetic photostimulation [ 15 ] as well as activation of the entire network by the chemical, CTZ, in a more physiologically relevant setting than in cultured cells.
1. Inject AAV carrying the desired LMO or iLMO gene into the brain region of interest in mice or rats . Wait at least 10 days after injection to allow adequate expression before carrying out experiments.
2. Prepare acute brain slices (~300 μm thick section s) using a vibratome.
3. Whole-cell patch clamp recordings are made similar to in vitro recordings using conventional methods. Recordings can be made from cells expressing LMOs or from cells receiving synaptic inputs from LMO-expressing neurons.
4. LMOs can be activated by photostimulation with an arc lamp, with laser spots for detailed photo-mapping of synaptic inputs, or by adding CTZ to the recording chamber (see above: Subheading 3.3 ).
5. For simultaneous imaging of bioluminescence, a camera can be used as described above (Subheading 3.3 , step 5 ). Alternatively, if working with a scanning microscope (i.e. confocal or twophoton microscope), a photodetector (i.e. a photomultiplier tube) can be used to record bioluminescence continuously. Switching to a lower magnifi cation lens will help to collect more photons.
For studying neuronal activity and/or behavior in awake animals expressing LMOs, viral vectors (generally AAV) are placed into the brain region of interest by stereotaxic injections as done for other optogenetic and chemogenetic approaches (Fig. 6 ) . The sections below focus on specifi c usage of LMOs.
For all in vivo experiments, CTZ preparations specifi cally designed for in vivo applications should be used (i.e. Nanolight Inject-ALume or water soluble CTZ). The choice of routes of delivery of CTZ in rodents depends on the goal of the experiment. Concentrations of CTZ should be aimed at fi nal concentrations in the animal of 100-200 μM ( see Note 12 ).
1. Intracranial injection : Concentrated CTZ in a minute volume can be delivered to a target brain region directly using an injection cannula inserted in the guide cannula (example: 34 ng CTZ in 0.4 μl PBS). Although this causes very rapid action only near the injection site, it may cause irreversible damage to the injection site if injection rate is too fast or large volumes are injected. (a) Retro-orbital injections in mice are an easy and reliable way of intravenous delivery, but usually require brief anesthesia.
(b) Tail vein injections in mice or rats can be done without anesthesia. The animals should be warmed up by a heat lamp to improve circulation. There are single-use catheters available for tail vein injections ( see Note 13 ).
(c) Jugular catheters in mice or rats offer an easy access port for repeated administration of precisely timed injections with defi ned concentrations (e.g. obtaining a dose-response curve). Note: catheters must be kept patent with bi-weekly fl ushing of heparin and gentamicin ( see Note 14 ).
3. Intraperitoneal injection: Application of substrate intraperitoneally results in a slower onset (several minutes) of measurable effects, which subside after a longer period of time (~30 up to 60 min) compared to intravenous injections. This is the route of choice for CTZ administrations repeatedly over long periods of time, for example to test the effects of chronic stimulation or In vivo bioluminescence imaging can be conducted as a means for noninvasive confi rmation of LMO expression and delivery of CTZ to a target. Imaging is conducted ideally with a dedicated small animal imager (e.g. IVIS imaging system). Depending on the species and area of expression in the brain, imaging can be conducted through the intact skull (Fig. 7 ) .
If such an imaging system is not available, other syst ems equipped with a cooled CCD camera or a sCMOS camera can be utilized, although with lower sensitivity. We have had success utilizing a gel image documenting system equipped with a cooled CCD camera (i.e. Fuji Film LAS-3000). In this pre-terminal setting, the skull of the animal was removed for bioluminescence imaging from the rat striatum ( see Note 15 ).
Since luminopsins modulate neuronal activity, their activity can be measured by any conventional means of in vivo extracellular recording in both acute and chronic settings. Implantable electrodes obtained commercially or custom-made electrodes/ optrodes (e.g. glass pulled electrodes, cannula-electrodes, or micro-drivable tetrodes such as FlexDrive, http://www.openephys.org/fl exdrive/ ; [ 16 ] ) are especially useful for recording both single-unit and local fi eld potentials of LMO-expressing cells. EEG electrodes can also be utilized depending on the extent of expression, but these approaches would be unable to detect changes at single-unit fi ring rates.
Luminopsins offer the ability for multiple modes of activation: by direct light stimulation and by chemical substrate. Either mode can be used as a control for the other because the same population of neurons is targeted with the same single molecule. This can be Fig. 7 Bioluminescence imaging in vivo. Lentivirus carrying synapsin-LMO1 (Gluc-ChR2-EYFP) was injected into the right premotor cortex of a mouse . A month later mice were imaged in vivo after intravenous injection of CTZ (luminescence), then perfused and brain-sectioned for fl uorescence imaging (fl uorescence) achieved using a cannula-electrode, whereby photostimulation (through a fi ber optic inserted through the cannula) and chemical stimulation (through injection of CTZ through the same cannula) can be restricted to only the neurons being recorded from. Cannula-electrodes can be fabricated by attaching guide cannulas to commercially available electrodes using superglue. These can be assembled before the actual implantation surgery to customize distance of the fi ber tip/injection cannula from the recording electrodes (Fig. 8 ) .
Bioluminescence Imaging In Vivo
Extracellular Recording In Vivo
The general procedure for recording responses of LMOexpressing cells to chemical and photostimulation is as follows:
1. Inject AAV into the rodent brains as described above. The amount of time for adequate expression will be specifi c to the construct/vector and will need to be empiri cally determined.
We typically wait at least 10 days for expression.
2. Commercially bought or custom-made electrodes/optrodes should be confi gured so that the intended target is covered with the appropriate number of recording contacts and is able to be illuminated by a fi ber optic (if included).
3. Stereotaxically implant the electrodes under anesthesia. Correct placement of the electrodes can be determined in real time by optically stimulating while advancing the electrode towards the intended target depth. The cell types being recorded can be determined by analyzing single-unit fi ring properties. After correct placement of the electrodes, a chronic implant can be created by securing everything to the skull via Fig. 8 Cannula-electrode. A 16-channel ele ctrode array ( left ) was superglued to a guide cannula ( right ). An optical fi ber was inserted through the cannula to illuminate cells while recording from them. Subsequent CTZ injections were also given through the same guide cannula skull screws and dental acrylic. A chronic implant will allow for multiple injections/stimulations within the same animal: we were able to record up to 3 months after viral injection.
4. Recordings from implanted electrodes can be carried out in freely moving animals before and after administration of CTZ as described in Subheading 3.7 above. The effect of CTZ can be determined by quantifying changes in the single-unit activity and low frequency power in the local fi eld potential.
5. Acute recordings can be conducted in head-fi xed awake or lightly anesthetized animals. Wait at least 10-15 min after advancing an electrode before collecting data ( see Note 16 ). Then establish a baseline before CTZ injection by recording at least 10-20 min without moving the probe. This is usually suffi cient to confi rm a stable recording and to capture characteristics of neurons at rest (but: see Note 17 ). Using an optrode (simultaneous recording and fi ber optic light stimulation) allows stimulation before and after CTZ administration: stimulation before is used to confi rm electrode location, and after to see if there are any remaining effects on driven activity as well as to confi rm that the same units were recorded for the duration of the trial.
Any behavioral test can be carried out in freely moving animals before and after administration of CTZ, acutely or to assess changes in behavior after chronic stimulation with bioluminescence. Combining behavioral assays with electrophysiological recording and/or bioluminescence imaging in a freely moving animal will offer a very unique application of LMOs. 4. Primary neurons of high quality can be isolated from freshly harvested embryonic day 18 rat pups, or from tissue pieces shipped the day before by BrainBits, Inc.
Notes
5. Prepare coated coverslips according to standard protocols. Pre-coated coverslips are also commercially available through NeuVitro and BD Biosciences.
Behavioral Testing
6. For lipofection of neurons replacing the transfection medium with the "preconditioned" medium within 4 h (can be shortened to 2 h) is critical for obtaining healthy neurons for patch clamp recordings.
7. A humidity chamber can be a plastic Tupperware box or pyrex glass dish containing a glass plate kept just above an inch of water. The glass plate holds the culture dishes. Another glass plate put on top of the container without completely closing it serves as lid.
8. For bath-application of CTZ, we do not recommend manual pipetting, which will likely disrupt electrophysiological recordings. A better way is to fi ll a line of Tygon or silicone tubing of small diameter with the CTZ solution, connect a syringe at the other end, and deliver it to the recording chamber through a micro-manifold with fl ow control (AutoMate Scientifi c) by manually pushing the plunger of the syringe. We had limited success by localized application with a Picospritzer: it seems CTZ oxidizes inside the glass pipette before the recording starts.
use a syringe with as little dead space as possible (Insulin syringes in either 0.3 or 0.5 ml sizes).
13. Instech Laboratories has a selection of catheters, connectors, and vascular access ports for rats and mice ( http://www. instechlabs.com/ ).
14. We typically push a mixture of 50 μl of heparin (30 U/ml) and 50 μl of Gentamicin (4 mg/ml) in sterile saline twice a week.
15. Whole animal imaging must be conducted with the animal under anesthesia, which may make it diffi cult to access peripheral veins for intravenous CTZ delivery due to vasoconstrictive effects of inhaled anesthetics like isofl urane.
16. The typical amount of wait time prior to starting baseline recording after electrode implantation takes into consideration deformation of tissue and transient depression in response to the mechanical stress. We found it important to be especially aware of this when using an optrode (custom made or commercially obtained). Even small-core fi ber optics are large when compared to extracellular electrode tips, including multicontact silicon probes. As a result, the tissue movement and recovery time can be greater. Advance slowly after penetrating the cortical surface, and while looking for responsive cells. After fi nding light-activated units at the tip of the probe (if using a multielectrode array), wait 5-10 min to see if they are stable, and whether they drift to another contact. Overall, regardless of the recording site, let the electrode sit 20-30 min before starting baseline recordings when using a typical optrode.
17. Longer times for establishing a baseline may be required when recording in a structure with very high variability or if the intent is to capture the effect of luminopsins on neural or behavioral state transitions, as a certain number of events would be needed.
